ArticleDevelopment & reproduction2024
Signal Transduction of Constitutive Activating and Inactivating Eel Lutropin/Choriogonadotropin Receptor (Eel LH/CGR) Mutants by Recombinant Equine Chorionic Gonadotropin (Rec-eCG).
Article in Development & reproduction, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lutropin/choriogonadotropin receptor (LH/CGR) is a member of the G protein-coupled receptor superfamily. LH/CGRs in fish and mammalian species have been reported to contain naturally occurring, constitutively activating, and inactivating mutations in highly conserved regions. The present study was designed to determine the functional aspect of eel LH/CGR signal transduction. Biochemical analysis was performed using cells transfected with wild-type eel LH/CG (eel LH/CGR-wt) or with activating (designated eel LH/CGR-M410T, L469R, and D590Y) and inactivating (eel LH/CGR-D 417N and Y558F) mutants. We also generated a mutant (eel LH/CGR-t651) in which the C-terminal cytoplasmic tail was truncated at residue 651. Activating mutant cells expressing eel LH/CGR-M410T, L469R, and D590Y exhibited 1.4-, 8.7-, and 4.0-fold increases in the basal cAMP response, respectively, without recombinant equine chorionic gonadotropin (rec-eCG) agonist treatment. In inactivating mutants (eel LH/CGR-D417N and Y558F), the cyclic adenosine monophosphate (cAMP) response did not result in completely impaired signal transduction. However, the eel LH/CGR-t651 mutant did not exhibit any cAMP signaling following high-agonist treatment. Rmax values did not increase with further rec-eCG agonist stimulation. Our results suggest that constitutively activating and inactivating eel LH/CGR mutants with highly conserved amino acids exhibit a significant signal transduction pathway for glycoprotein hormone receptors. Eel LH/CGRs in activating and inactivating mutants are usually processed by receptor-mediated signaling following rec-eCG agonist stimulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.